2020
DOI: 10.1007/s11051-020-05030-2
|View full text |Cite
|
Sign up to set email alerts
|

Research progress of nanomaterial-mediated photodynamic therapy in tumor treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 71 publications
0
10
0
Order By: Relevance
“…Generally, NPs with diameters of 50−100 nm are suitable for prolonging blood circulation and can effectively accumulate in tumors through the EPR effect. 54 As a phototherapeutic agent targeting tumors through intravenous injection, BITT@BSA−DSP should be an improved choice. Different feeding mass ratios of BITT to BSA with values of 5%, 10%, 15%, and 20% (w/w) were measured to determine their effects on the diameter, ROS generation capability, and photothermal conversion performance of the NPs (Figure S4 and Table S1).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Generally, NPs with diameters of 50−100 nm are suitable for prolonging blood circulation and can effectively accumulate in tumors through the EPR effect. 54 As a phototherapeutic agent targeting tumors through intravenous injection, BITT@BSA−DSP should be an improved choice. Different feeding mass ratios of BITT to BSA with values of 5%, 10%, 15%, and 20% (w/w) were measured to determine their effects on the diameter, ROS generation capability, and photothermal conversion performance of the NPs (Figure S4 and Table S1).…”
Section: Resultsmentioning
confidence: 99%
“…As shown in Figure C and D and Table S1, the DLS and TEM data showed that the average diameter of BITT@BSA–DSP NPs was 70.2 ± 22.0 nm (polydispersity index (PDI): 0.13). Generally, NPs with diameters of 50–100 nm are suitable for prolonging blood circulation and can effectively accumulate in tumors through the EPR effect . As a phototherapeutic agent targeting tumors through intravenous injection, BITT@BSA–DSP should be an improved choice.…”
Section: Resultsmentioning
confidence: 99%
“…PDT has been studied as an immunogenic cell death (ICD) inducer for eliciting direct tumor-killing effects through the creation of tumor antigen pools with danger signals that promote cancer-specific immunity [20]. Photosensitizers (PS) can produce reactive oxygen species (ROS) in response to exposure to a certain wavelength, which can then kill surrounding cancer cells by necrotic or apoptotic cell death [20]. Owing to the highly enriched distinctive physical and chemical characteristics, CDs have been applied in the synergistic treatment of PDT and immunotherapy [21].…”
Section: Immunotherapy Applications Of Carbon Dots Pdtmentioning
confidence: 99%
“…In addition to their multicolored emission, tunable optical properties, and outstanding photostability, CDs can also be used as efficient tools for tumor therapy owing to their easy surface functionalization and excellent biocompatibility [14,19]. On the one side, CDs can be employed as phototherapy agents, including photodynamic therapy (PDT) and photothermal therapy (PTT) [20,21]. On the other side, the rational design would confer CDs the properties of nanoenzymes or chemotherapeutic agents involved in tumor chemodynamic therapy (CDT) [22].…”
Section: Introductionmentioning
confidence: 99%
“…The chemokine receptors dysregulated in HSCs contain CXC chemokine receptor 3 (CXCR3); C–C chemokine receptor (CCR) family, including CCR5 and CCR7( Seki et al, 2009 ). The chemokine family chain in HSCs contains the chemokine ligand (CCL) family, which includes CCL2, CCL3, and CCL5; in addition, the CXC chemokine ligand (CXCL) family contains CXCL1 and CXCL8–CXCL10 ( Weiskirchen and Tacke 2014 ; Yan et al, 2020 ). Generally, the chemokines bind to their receptors to promote HSC migration and ECM generation.…”
Section: Introductionmentioning
confidence: 99%